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Background: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has markedly increased over the
last three decades due to newly found associations with human papillomavirus (HPV) infection. Primary
radiotherapy (RT) is the treatment of choice for OPSCC at most centers, and over the last decade, the addition of
concurrent chemotherapy has led to a significant improvement in survival, but at the cost of increased acute and
late toxicity. Transoral robotic surgery (TORS) has emerged as a promising alternative treatment, with preliminary
case series demonstrating encouraging oncologic, functional, and quality of life (QOL) outcomes. However,
comparisons of TORS and RT in a non-randomized fashion are susceptible to bias. The goal of this randomized
phase II study is to compare QOL, functional outcomes, toxicity profiles, and survival following primary RT
(± chemotherapy) vs. TORS (± adjuvant [chemo] RT) in patients with OPSCC.
Methods/Design: The target patient population comprises OPSCC patients who would be unlikely to require
chemotherapy post-resection: Tumor stage T1-T2 with likely negative margins at surgery; Nodal stage N0-2, ≤3 cm
in size, with no evidence of extranodal extension on imaging. Participants will be randomized in a 1:1 ratio
between Arm 1 (RT ± chemotherapy) and Arm 2 (TORS ± adjuvant [chemo] RT). In Arm 1, patients with N0 disease
will receive RT alone, whereas N1-2 patients will receive concurrent chemoradiation. In Arm 2, patients will undergo
TORS along with selective neck dissections, which may be staged. Pathologic high-risk features will be used to
determine the requirement for adjuvant radiotherapy +/- chemotherapy. The primary endpoint is QOL score using
the M.D. Anderson Dysphagia Inventory (MDADI), with secondary endpoints including survival, toxicity, other QOL
outcomes, and swallowing function. A sample of 68 patients is required.
Discussion: This study, if successful, will provide a much-needed randomized comparison of the conventional
strategy of primary RT vs. the novel strategy of primary TORS. The trial is designed to provide a definitive QOL
comparison between the two arms, and to inform the design of an eventual phase III trial for survival outcomes.
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The incidence of oropharyngeal squamous cell carcinoma
(OPSCC) is rapidly increasing, associated with rising rates
of oral infection with the human papillomavirus (HPV)
[1]. Patients with HPV-related cancers tend to present at a
younger age and experience markedly improved survival,
compared to patients with smoking- and alcohol-related
head and neck cancers [1]. In such young patients with
good prognosis, survivorship is of paramount importance,
as they are likely to survive their cancer and may have to
cope with the side effects of therapy and secondary dis-
ability for decades. Optimizing post-treatment quality of
life (QOL) for patients with OPSCC has become one of
the most important issues in head and neck oncology.
Historically, oropharyngeal cancer was frequently man-
aged with open surgery, with or without postoperative
radiotherapy (RT). Although this approach was reasonably
effective at obtaining tumor control, the speech, swallowing
and cosmetic outcomes were poor. Surgical access of the
oropharynx traditionally involves large facial and neck
incisions that interrupted critical neurovascular and
muscular structures [2]. This resulted in high complica-
tion rates, leading many centers to move towards organ
preservation approaches utilizing radiation as primary
treatment with surgery reserved for salvage [3]. Al-
though a randomized trial was never carried out com-
paring surgery and RT, a meta-analysis of observational
studies demonstrated that primary surgery and primary
RT approaches were equivalent in terms of survival, but
major complications of therapy were markedly worse in
the primary surgery patients [2].
For patients with high-risk cancers of the oropharynx,
concurrent cisplatin-based chemotherapy is delivered
with RT and achieves a significant improvement in sur-
vival, compared to radiotherapy alone [4]. However, it is
increasingly recognized that these improvements in sur-
vival come at the cost of increased acute and late toxicities:
these include dysphagia, mucositis, xerostomia, fibrosis,
osteoradionecrosis, neutropenia, neurotoxicity, nephrotox-
icity and ototoxicity [5]. The addition of chemotherapy to
RT increases the risk of long-term gastrostomy tube
dependence from 1% to 13% [5]. These treatment-
related toxicities can significantly affect QOL.
These toxicity risks, and their consequent reduction in
QOL, have led to increasing interest in minimally inva-
sive surgical approaches for OPSCC, especially transoral
robotic surgery (TORS) using a surgical robot. The sur-
gical robot is comprised of a binocular endoscope and
two low profile articulating arms that can be placed in
the oropharynx, while the surgeon sits at a separate con-
sole to control the instruments. This allows the operat-
ing surgeon to overcome the visualization and access
challenges that can otherwise make transoral surgery in
this area challenging, if not impossible. The ability toavoid incisions in the face and neck, which were
required prior to the implementation of the robot, pre-
serves neuromuscular structures that are critical for
speech and swallowing. Preliminary case series of TORS
have reported encouraging oncologic, functional, and
QOL outcomes compared with primary RT [6,7].
Outcomes after TORS have been summarized in a
recent systematic review [6]. All reports involve pro-
spective or retrospective single-arm case series with
varying use of adjuvant therapy without adequate con-
trols. This is in stark contrast to the large number of
randomized controlled trials of chemoradiation (CRT)
for OPSCC. Favourable gastrostomy tube rates (0–9.5%
at one year and 0% at two years post treatment) have
been reported following TORS [6]. In contrast, feeding
tube rates in CRT series range from 9 to 39% at one
year [8,9]. Patients undergoing TORS experience excel-
lent 2-year disease free survival (DFS) and overall sur-
vival (OS) rates of 79% to 89% and 82% to 90%,
respectively [6]. CRT trials report 3-year DFS and OS rates
of 42% to 76.5% and 51% to 85%, respectively [8,9]. Two
studies have explored the impact of TORS on QOL. Pa-
tients receiving TORS alone report better health-related
QOL compared to individuals receiving TORS plus adju-
vant radiation or chemoradiation [7]. Swallowing-related
QOL is reported to decrease immediately following TORS
intervention, but has been demonstrated to improve by
one year post-treatment, with possible further improve-
ment thereafter [10].
Although these data would appear to favor a surgical
approach, a careful review of the literature reveals that this
is a tremendously biased comparison. The TORS studies
include a much smaller fraction of T3/T4 tumors (0–30%)
and N3 neck disease (0–4%) compared with CRT series
(31–86% T3/T4 and 2.5–12% N3) [6,8,9]. There are nu-
merous additional confounders that make these compari-
sons invalid including: 1) patients receiving surgery have
been carefully selected (i.e. ‘confounding by indication’,
which cannot be adequately controlled for in observa-
tional studies [11]), 2) each study contains a different frac-
tion of HPV-positive tumors, and 3) the majority of TORS
patients receive adjuvant therapy including radiation
(24%) or chemoradiation (54%) [12], making the true
benefits of TORS unclear. Not surprisingly, management
of OPSCC is now one of the most contentious and im-
portant issues in head and neck oncology practice in the
wake of the growing HPV OPSCC epidemic.
Given the rapid treatment paradigm shift in the
absence of level I evidence, the high cost of acquiring a
surgical robot, and increasing numbers of affected
patients due to the HPV epidemic, a randomized trial is
critical to guide the optimal management of OPSCC.
The goal of this randomized phase II study is to formally
compare QOL in patients with oropharyngeal cancer
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the design of a large, definitive, comparative phase III
trial assessing survival.
Methods/Design
This study has been approved by the Ontario Cancer
Research Ethics Board (#12-006), in compliance with
the Helsinki Declaration.
Objectives
To compare QOL after primary radiotherapy [± chemo-
therapy] (Arm 1) vs. TORS [± adjuvant (chemo)radiother-
apy] (Arm 2) in patients with squamous cell carcinoma of
the oropharynx, to compare toxicity profiles, and to con-
duct a non-definitive comparison of survival between the
two modalities. (See Figure 1 - Study Schema and Figure 2-
Timeline of Interventions)
Primary endpoint
 QOL 1-year post-treatmentFigu○ Assessed with the MD Anderson Dysphagia
Inventory (MDADI)Secondary endpoints
 Overall Survival
○ Defined as time from randomization to death
from any cause Progression-free survival
○ Time from randomization to disease
progression at any site or deathre 1 Study schema. HPV: human papilloma virus; quality of life: QOL. QOL at other time points
○ Using the MD Anderson Dysphagia Inventory
(MDADI), the EORTC QLQ-C30 and H&N35
scales, the Voice Handicap Index (VHI-10), the
Neck Dissection Impairment Index (NDII), and
the Patient Neurotoxicity Questionnaire (PNQ).
 Toxicity
○ Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4 Swallowing function, measured by:
○ Feeding tube rate at 1-year
○ MDADI
○ CTC-AE Dysphagia scoresInclusion criteria
 Age 18 or older, providing informed consent
 ECOG performance status 0–2
 Histologically confirmed squamous cell carcinoma
 Primary tumor site in the oropharynx (includes tonsil,
soft palate, base of tongue, walls of oropharynx)
 Tumor stage: T1 or T2, with likely negative
resection margins at surgery
 Nodal stage: N0, N1 (≤ 3 cm), or N2 (between
1–3 cm, on either side of the neck), without
extranodal extension on pre-randomization imaging.
 CBC/differential obtained within 4 weeks prior to
randomization, with adequate bone marrow function,
hepatic, and renal function, defined as: Hemoglobin >
80 g/L; Absolute neutrophil count >1.5 × 109 /L,
platelets > 100 × 109/L; Bilirubin < 35 umol/L; AST or
Figure 2 Timeline of interventions.
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130 umol/L or creatinine clearance ≥ 50 mL/min
 Patient assessed at head and neck multidisciplinary
clinic (with assessment by radiation oncologist and
surgeon) and presented at multidisciplinary tumor
board prior to randomization.
Exclusion criteria
 Serious medical comorbidities or other
contraindications to radiotherapy, chemotherapy or
surgery
 Prior history of head and neck cancer within 5 years
 Prior head and neck radiation at any time
 Metastatic disease
 Inability to attend full course of radiotherapy or
follow-up visits
 Prior invasive malignant disease unless disease-free
for at least 5 years or more, with the exception of
non-melanoma skin cancer
 Unable or unwilling to complete QoL questionnaires
 Pregnant or lactating women
Evaluation
The following evaluations are required:
 History and physical examination by a radiation
oncologist and head and neck surgeon within
8 weeks prior to randomization, including
laryngopharyngoscopy.
 Staging within 12 weeks prior to randomization:
○ Contrast-enhanced CT of the head, neck, and chest
or
○ MRI of the head and neck with CT of the chest Histological confirmation of squamous cell
carcinoma
 p16 or HPV tumor status
 CBC/differential, hepatic and renal function testing
within 4 weeks of randomization
 Pregnancy test for women of child-bearing age
within 2 weeks of randomization
 Dental evaluation within 6 weeks of randomization
 Assessment of dysphagia using CTC-AE version 4
within 2 weeks of randomization
 Completion of QOL scoring within 2 weeks of
randomization
 Blood sample for mutational and copy number
variation analysis (see section) within 4 weeks of
randomization
 Signing of consent within 2 weeks of randomization
 Audiogram before initiation of treatmentTreatment plan
Arm 1: Radiotherapy
Intensity modulated radiotherapy (IMRT) will be used for
all patients in this study. IMRT can be delivered using
fixed-gantry techniques or rotational techniques (e.g.
Tomotherapy or Volumetric Modulated Arc Therapy
[VMAT]). Doses and fractionations are shown in Table 1.Immobilization and localization
All patients will be immobilized in a custom thermoplas-
tic shell and will undergo a planning CT simulation
encompassing the head and neck to below the clavicles.
Contrast will be used (unless contra-indicated) for
patients in Arm 1. For patients in both arms, the plan-
ning CT will be fused with other diagnostic imaging
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in Arm 2) where necessary.Radiotherapy volume definitions
Arm 1
The gross tumor volume (GTV) is defined as the tumor
and any nodes that are either: 1 cm or more in short
axis, necrotic, PET positive (where applicable) or biopsy-
proven to contain carcinoma. A 5 mm expansion will be
added to create the clinical target volume (CTV) CTV70
(excluding natural boundaries of spread), with a further
5 mm to create the planning target volume (PTV) PTV70,
which will be treated to a dose of 70 Gy in 35 fractions.
An optional high-risk nodal volume (CTV63) may be
defined for areas of uncertainty (e.g. suspicious nodes
not meeting the criteria above). A 5 mm margin will be
added to create the PTV63, which will be treated to a
dose of 63 Gy in 35 fractions.
A lower-risk nodal volume (CTV56) will be defined to
include the standard lymphatic drainage sites. For well-
lateralized, node-negative tonsillar primaries, this can be
limited to the ipsilateral neck; for primaries at the
tongue base, this must include both sides of the neck.
For patients with a positive node, the contralateral neck
must be treated. A 5 mm margin will be added to create
the PTV56, which will be treated to a dose of 56 Gy in
35 fractions.
In Arm 1, accelerated or hyperfractionated regimens
may be used at the discretion of the radiation oncologist
(e.g. same doses but delivered in 6 weeks by delivering 5
twice-daily (BID) treatments, maximum one BID treat-
ment per week)Arm 2
The highest-risk volume (CTV64) will consist of regions
of positive margins or extra-nodal extension. A 5 mm
margin will be added to create the PTV64, which will be
treated to a dose of 64 Gy in 30 fractions.
An intermediate-risk volume (CTV60) will be defined
to include the entire tumor bed. CTV60 will also include
the pathologically-positive neck. If both sides of the neck
are pathologically positive, then both are treated to 60 Gy.
A 5 mm margin will be added to create the PTV60, which
will be treated to a dose of 60 Gy in 30 fractions.Table 1 Radiotherapy doses and fractionations
Target volume Radical-
Gross tumor and nodes 70 Gy in 3
Region of positive margins or extra-nodal extension
High-risk nodal areas (and operative bed in Arm 2) 63 Gy in 3
Low-risk nodal areas 56 Gy in 3
*In Arm 1, accelerated or hyperfractionated regimens may be used at the discretionA lower-risk nodal volume (CTV54) can be defined to
include the standard lymphatic drainage sites that have
not been dissected and/or low-risk dissected sites. For
patients with a positive node, this will include the
contralateral neck. A 5 mm margin will be added to
create the PTV54, which will be treated to a dose of
54 Gy in 30 fractions.
Dose constraints
Target dose constraints are shown in Additional file 1:
Appendix 1, adapted from RTOG protocols 1016 (Arm 1)
and 0920 (Arm 2) [13], and the NCIC-CTG HN6 proto-
col. Dose constraints are the same for both arms as the
radiobiological conversion factor is small.
Radiotherapy planning
Intensity modulated radiotherapy (IMRT) will be used
for all patients in this study. IMRT can be delivered
using fixed-gantry techniques or rotational techniques
(e.g. Tomotherapy or Volumetric Modulated Arc Ther-
apy [VMAT]). All plans will be normalized to ensure
that 95% of each PTV is covered by 95% of the prescrip-
tion dose for that volume. The maximum dose to
PTV70 (Arm 1) and PTV64 (Arm 2) should not exceed
110% of the prescribed dose, and no volume >1 cc out-
side of these two PTVs should receive >105% of the pre-
scription dose.
Radiotherapy quality assurance
In order to ensure patient safety and effective treatment
delivery, a robust quality assurance protocol is incorpo-
rated. The following requirements must be completed
for each patient:
 Prior to treatment, each radiotherapy plan will be
discussed at head and neck quality assurance (QA)
rounds.
 All dose delivery for intensity-modulated plans
(including arc-based treatments) will be verified
with phantom measurements before treatment by
physics staff.
 Cone-beam CT will be used to verify patient
positioning immediately prior to treatment at
minimum on a weekly basis, with orthogonal x-rays
used on other days.intent dose* (Arm 1) Adjuvant dose (Arm 2)
5 fractions over 7 weeks N/A
N/A 64 Gy in 30 fractions over 6 weeks
5 fractions over 7 weeks 60 Gy in 30 fractions over 6 weeks
5 fractions over 7 weeks 54 Gy in 30 fractions over 6 weeks
of the radiation oncologist (e.g. same doses but delivered in 6 weeks).
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Patients with T1-T2N0 tumors will receive radiotherapy
alone, and patients with T1-2 N1-2 tumors will receive
radiotherapy with concurrent systemic therapy. Chemo-
therapy will consist of cisplatin 100 mg/m2 delivered
every 3 weeks, in 3-week cycles. For patients who are
deemed unfit for high dose cisplatin, the dose and/or
schedule can be modified, or cetuximab or weekly
carboplatin AUC 1.5 can be used, at the discretion of
the medical oncologist.
Salvage surgery in arm 1
Treatment response will be evaluated 8–10 weeks after
completion of radiation therapy. For patients with
residual nodes > 1 cm in size, a salvage neck dissection
will be done. For patients with relapse or progressive
disease at any time subsequent to radiation treatment,
surgical salvage will be offered if feasible.
Arm 2: TORS
TORS for the primary tumor
For patients with easily accessible oropharyngeal tumors
as determined by the consulting surgeon, they will
proceed directly to transoral robotic surgery. For pa-
tients where adequate transoral access is in question,
they will first undergo an examination under anesthesia
prior to randomization to ensure adequate exposure can
be obtained.
TORS will be carried out using the da Vinci surgical
robot (Intuitive Surgical, Sunnyvale, CA, USA). The
spatula cautery will be used to remove the tumors with
1 cm margins. At the time of surgery circumferential
margins will be taken and sent for frozen section ana-
lysis. The resection will proceed until negative margins
are obtained if feasible. The learning curve for surgeons
carrying out TORS resections has been demonstrated to
be short for early-stage cases, likely fewer than 10 cases,
with improvements in operative time (but not oncologic
outcomes) evident as learning occurs [14]. As a result,
surgeons will be required to have carried out at least 10
TORS operations prior to enrolling patients on this trial.
If a positive or close margin is found on the final path-
ology from the TORS resection, an attempt to clear the
margin transorally may be performed within four weeks
of the original TORS resection. This can be done with
or without the robot at the surgeon’s discretion.
Neck dissection
Patients will undergo standard selective neck dissections
for the lymph node areas at risk at the time of TORS, or
as a staged procedure within three weeks of the primary
site resection, at the discretion of the surgeon. Patients
with tonsillar, lateral pharyngeal and lateral palate can-
cers will undergo ipsilateral neck dissections only, whileall other patients will undergo bilateral neck dissections.
If levels 1 or 5 are involved they will be dissected, other-
wise selective neck dissections will be limited to levels
2–4. For patients with positive margins at the primary
site at the time of TORS, an attempt can be made at the
time of neck dissection to clear the positive margin
transorally.
Adjuvant radiotherapy and chemotherapy
Adjuvant radiotherapy and chemotherapy will be delivered
in accordance with National Comprehensive Cancer
Network (NCCN) Clinical Guidelines [15]. Radiotherapy
prescriptions and planning details are outlined above.
Radiotherapy can be omitted if there are no adverse
pathological features (i.e. none of the following: extranodal
extension, positive margins, pT3 or pT4 disease, nodal
disease, or lymphovascular invasion).
Adjuvant radiotherapy alone is recommended for the
following risk factors:
 Any node positive
 Lymphovascular invasion
 pT3 or pT4 tumor
 Close resection margins (<2 mm)
For patients with perineural invasion (PNI) alone and
no other indications for radiotherapy, radiotherapy will
be omitted [16].
Adjuvant chemotherapy concurrent with radiotherapy
is required for patients with positive margins or extra-
capsular extension. The chemotherapy will consist of
cisplatin 100 mg/m2 delivered every 3 weeks, in 3-
week cycles. For patients who are deemed unfit for such
chemotherapy, the dose and/or schedule can be modi-
fied, or weekly carboplatin AUC 1.5 can be utilized, at
the discretion of the medical oncologist.
Follow-up evaluation and assessment of efficacy
The follow-up schedule is shown in Additional file 2:
Appendix 2. Day 1 of follow-up will be the first day of
radiotherapy (Arm 1) or the date of surgery (Arm 2);
however, survival will be calculated from the date of
randomization.
Arm 1: For patients receiving radiotherapy, they will
be seen weekly during radiotherapy, and 4–6 weeks after
radiotherapy, as part of routine care. A CT scan of the
neck will be carried out 8–10 weeks after radiotherapy
for assessment of residual disease for neck dissection,
with a routine radiotherapy appointment 2 weeks after
the CT scan (approximately 4 months from the start of
treatment).
Arm 2: Patients will be seen approximately 2 weeks
after completion of the neck dissection for routine post-
operative assessment. Adjuvant radiotherapy, if required,
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be pre-booked to start within 6 weeks of the date of
TORS to avoid unnecessary delays. During radiotherapy,
routine visits will occur weekly during radiotherapy and
4–6 weeks afterward. For all patients in Arm 2, a return
visit with the surgeon will occur at 3 months from the
date of TORS.
Both arms: In addition to the above, patients will be
seen at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and
60 months from first date of treatment. At each visit, a
history and physical examination will be conducted
(including laryngopharyngoscopy), and CTC-AE toxic-
ities recorded. The QOL questionnaires are to be com-
pleted every 6 months except for the Patient Neurotoxicity
Questionnaire (PNQ) that will be completed one year
post-treatment. A chest x-ray will be completed every
6 months (except at the 12 month visit when a CT
chest is undertaken). One year post-randomization, an
audiogram should be performed.
For patients in both arms, a CT of the head, neck, and
chest will be done at 12 months. Additional imaging or
laboratory investigations should be carried out at the
discretion of the oncologist, based on findings in the his-
tory or physical, and additional treatment (e.g. salvage
treatment) is at the discretion of the treating physicians.
During treatment, blood tests will be performed as per
standard of care and highest BUN and creatinine values
and lowest white blood cell, neutrophil and platelet
counts will be recorded. One year post-treatment, a
blood test to measure BUN, creatinine, and CBC/differ-
ential will be performed.
Measurement of response
Survival outcomes: Overall survival will be measured as
time from randomization until death from any cause,
and progression-free survival as time to either progres-
sion or death, whichever occurs first.
QOL outcomes: The MDADI, EORTC scales, NDII, and
VHI-10 will be measured at baseline and at 6-month
intervals. PNQ will be completed at 1 year post-treatment.
Toxicity outcomes: CTC-AE toxicities will be recorded
at every follow-up visit (3, 6, 9, 12, 15, 18, 21, 24, 30, 36,
42, 48, 54, and 60 months from the first date of
treatment).
Quality assurance for sites joining trial
The “learning curve” associated with TORS has been
reported as a minimum of approximately 10 cases, with
improvements in operating time noted after such learn-
ing is complete [14]. Importantly, such learning did not
appear to affect the rates of positive margins. Prior to
opening the study, in addition to local research ethics
approval, each surgeon enrolling patients onto trial must
have completed at least 10 previous TORS cases, andone such case will be proctored by one of the Principal
Investigators (ACN). Each centre will be required to
complete mock radiotherapy treatment plans, to ensure
that such plans are designed in compliance with the
protocol. The principal investigators will provide pertin-
ent CT datasets. There will be three such mock plans:
one node-negative radical case, one node-positive radical
case, and one adjuvant case. Once these have been re-
ceived and approved, the centre can be activated. Once
the study is open, each centre may enroll and treat pa-
tients. For each patient enrolled on study and receiving
radiation therapy, an electronic copy of the full radiation
treatment plan must be sent to the principal investiga-
tors on or before the first day of treatment. Radiotherapy
treatment can begin, but the plan will be reviewed
within 5 business days to ensure there are no major de-
viations from the protocol.
Statistics and sample size calculation
The study will employ a 1:1 randomization between
Arm 1:Arm 2 (Figure 1) in a permutated block design.
This sample size allows for one stratification factor at
randomization, which will be HPV status: (positive vs.
negative/indeterminate)
Sample size considerations
This study will employ a randomized phase II screening
design, to conduct a definitive QOL comparison as the
primary endpoint, along with preliminary and non-
definitive overall survival comparison between the two
arms as a secondary endpoint [17]. The primary end-
point is the total score on all twenty items of the
MDADI. It is generally believed that a 10-point differ-
ence in standardized QOL scores represents a clinically
significant difference in QOL [18]. It is assumed that the
QOL scores will be normally distributed with a standard
deviation of 12. The study will use a two-sided,
independent-sample t-test with an alpha level of 0.05
and power of 90%, and assume a dropout rate of 10%.
There will be a 1:1 randomization between Arm 1 and
Arm 2. In order to detect a 10-point improvement in
QOL in the TORS arm (Arm 2), a total of 68 patients
will be required (34 in each arm). Accrual targets are as
follows: 10 patients in year 1, and 15–20 patients in
years 2, 3, and 4.
Analysis plan
Patients will be analyzed in the groups to which they are
assigned (intention-to-treat).
An independent-sample t-test will be used to compare
QOL scores at 1-year on the MDADI. The percent of
patients in each arm who experience a clinically signifi-
cant QOL decline (10 points) will also be reported. Sur-
vival will be calculated from date of randomization using
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using the log-rank test. Pre-planned subgroup analysis
will occur based on the stratification variable. A Cox
multivariable regression analysis will be used to deter-
mine baseline factors predictive of survival. For the sec-
ondary endpoints involving QOL scales, linear mixed
effects models will be used; for the MDADI, NDII and
VHI-10, the total scores will be compared between the
two arms, whereas for the EORTC scales, each of the
subscales (e.g. pain, swallowing, etc.) will be compared
between the two arms. The PNQ scores (A to E) will be
converted to a numerical score (0 to 4, respectively), and
the mean scores in each group will be compared with a
t-test. In addition, the proportion of patients reporting
severe neurological dysfunction (D or E) will be com-
pared with the Chi-Squared Test, or Fisher's exact test,
as appropriate.
Data Safety Monitoring Committee (DSMC)
The DSMC, consisting of at least one radiation oncolo-
gist, one medical oncologist, and surgical oncologist not
involved in the study, will meet quarterly after study ini-
tiation to review toxicity outcomes. If any grade 3–5 tox-
icity is reported, the DSMC will review the case notes to
determine if such toxicity is related to treatment. If the
DSMC deems that toxicity rates are excessive (e.g. >5%
grade 4 or 5 toxicity), then the DSMC can, at its discre-
tion, recommend modification or cessation of the trial.
Interim analysis: the DSMC will conduct one interim
analysis once 30 patients have been accrued and
followed for 1-year. For this analysis, the DSMC will be
blinded to the identity of each treatment arm, but QOL
and OS data will be presented for each arm.
The DSMC will recommend stopping the trial if there
is an OS difference that is statistically significant with a
threshold of p < 0.001 using the log-rank test, based on
the Haybittle-Peto stopping rule; this retains an overall
alpha of 0.05. Furthermore, if the QOL scores among all
patients are substantially different than estimated in the
sample size calculation, the DSMC can recommend in-




P16 testing (which is an excellent surrogate marker of
HPV status) is required for stratification at the time of
randomization. This will be done through the routine
pathology laboratories as per current routine clinical care.
The accompanying biomarker study will determine
HPV status by real-time polymerase chain reaction
(PCR), not for the purposes of randomization, but to
confirm the accuracy of P16 results and also for
subtyping of HPV strain. For patients randomized toradiotherapy, pre-treatment formalin fixed paraffin
embedded (FFPE) primary site biopsy specimens will be
retrieved in 10 slides 8um thick from the FFPE blocks.
For patients randomized to TORS, the main specimen
will be taken to pathology frozen section room and a
portion from the center of the specimen will be taken
with the assistance of the pathologist and frozen at -80
degrees Celsius. DNA will be extracted from the speci-
mens for HPV testing by real-time PCR.
Mutational and copy number variation analysis
DNA will be extracted either from formalin fixed speci-
mens or preferably fresh tumor for patients undergoing
TORS as well as 10 mL of venous blood drawn prior to
the initiation of treatment. Specimens yielding DNA of
adequate quantity and quality (>5 μg, OD between 1.8
and 2.0) will be subjected to high-throughput sequen-
cing and gene copy number analysis.
Discussion
In the wake of the HPV oropharyngeal cancer epidemic,
it is imperative that we have treatment strategies that
optimize post-treatment QOL for these younger, health-
ier patients. Radiation therapy (+/- chemotherapy) has
been proven highly effective and provides a high QOL
for most patients; however, a subset can suffer significant
toxicity including severe dysphagia requiring gastros-
tomy tube dependence. Although the preliminary out-
comes of TORS are encouraging, rapid adoption has
occurred in the United States without clear evidence
that it provides equivalent or superior QOL and survival
outcomes. It is critical that this question be answered in
a systematic way to either support this change in treat-
ment strategy or halt this transition. The results of this
study have the potential to guide improvements in the
QOL of patients with OPSCC in Canada and worldwide.
The implementation of new technologies in medicine
often follows Roger’s innovation adoption life-cycle: after
the technique is developed by innovators, it is taken up by
early adopters, followed by the early- and late- majority,
and then laggards in a bell-curve distribution [19]. The
ideal time to test a new innovation is at the early-adoption
/early majority phase, as after a technique is widely
adopted, benefits can be assumed (sometimes errone-
ously) and equipoise is lost [20]. TORS is at this juncture
in Canada, with early adopters having implemented
the technique, with several other centres planning to
implement the technology over the next few years. This
provides a key opportunity to test the benefits of TORS.
Identification of biomarkers of radiation or surgical
failure would be highly useful to guide patients toward
therapies with the highest chance of cure while avoiding
unnecessary toxicity. A randomized trial is the ideal set-
ting for biomarker discovery as confounding factors are
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mary tumor and blood samples will undergo whole
exome sequencing with copy number analysis. Although
the study is not powered for biomarker discovery, the
next generation analysis may reveal interesting genetic
findings comparing HPV positive and negative cancers.
Should a phase III trial be warranted, biomarker discov-
ery will be an integral component in order to identify in-
dividuals who would benefit the most from either
modality or are at high-risk of treatment related toxicity
such as ototoxicity. Reliable biomarkers would represent
a tremendous step towards customizing care for the
increasing number of patients suffering with OPSCC.
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